Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Identifieur interne : 000620 ( Main/Exploration ); précédent : 000619; suivant : 000621Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
Auteurs : Ana I. Rojo [Espagne] ; Nadia G. Innamorato [Espagne] ; Ana M. Martín-Moreno [Espagne] ; María L. De Ceballos [Espagne] ; Masayuki Yamamoto [Japon] ; Antonio Cuadrado [Espagne]Source :
- Glia [ 0894-1491 ] ; 2010-04.
English descriptors
Abstract
Neural injury leads to inflammation and activation of microglia that in turn may participate in progression of neurodegeneration. The mechanisms involved in changing microglial activity from beneficial to chronic detrimental neuroinflammation are not known but reactive oxygen species (ROS) may be involved. We have addressed this question in Nrf2‐knockout mice, with hypersensitivity to oxidative stress, submitted to daily inoculation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) for 4 weeks. Basal ganglia of these mice exhibited a more severe dopaminergic dysfunction than wild type littermates in response to MPTP. The amount of CD11b‐positive/CD45‐highly‐stained cells, indicative of peripheral macrophage infiltration, did not increase significantly in response to MPTP. However, Nrf2‐deficient mice exhibited more astrogliosis and microgliosis as determined by an increase in messenger RNA and protein levels for GFAP and F4/80, respectively. Inflammation markers characteristic of classical microglial activation, COX‐2, iNOS, IL‐6, and TNF‐α were also increased and, at the same time, anti‐inflammatory markers attributable to alternative microglial activation, such as FIZZ‐1, YM‐1, Arginase‐1, and IL‐4 were decreased. These results were confirmed in microglial cultures stimulated with apoptotic conditioned medium from MPP+‐treated dopaminergic cells, further demonstrating a role of Nrf2 in tuning balance between classical and alternative microglial activation. This study demonstrates a crucial role of Nrf2 in modulation of microglial dynamics and identifies Nrf2 as molecular target to control microglial function in Parkinson's disease (PD) progression. © 2009 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/glia.20947
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease</title><author><name sortKey="Rojo, Ana I" sort="Rojo, Ana I" uniqKey="Rojo A" first="Ana I." last="Rojo">Ana I. Rojo</name></author><author><name sortKey="Innamorato, Nadia G" sort="Innamorato, Nadia G" uniqKey="Innamorato N" first="Nadia G." last="Innamorato">Nadia G. Innamorato</name></author><author><name sortKey="Martin Oreno, Ana M" sort="Martin Oreno, Ana M" uniqKey="Martin Oreno A" first="Ana M." last="Martín-Moreno">Ana M. Martín-Moreno</name></author><author><name sortKey="De Ceballos, Maria L" sort="De Ceballos, Maria L" uniqKey="De Ceballos M" first="María L." last="De Ceballos">María L. De Ceballos</name></author><author><name sortKey="Yamamoto, Masayuki" sort="Yamamoto, Masayuki" uniqKey="Yamamoto M" first="Masayuki" last="Yamamoto">Masayuki Yamamoto</name></author><author><name sortKey="Cuadrado, Antonio" sort="Cuadrado, Antonio" uniqKey="Cuadrado A" first="Antonio" last="Cuadrado">Antonio Cuadrado</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C2FD69B7B8C27492BD436920C88B658D0F43E23F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/glia.20947</idno><idno type="url">https://api.istex.fr/document/C2FD69B7B8C27492BD436920C88B658D0F43E23F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002324</idno><idno type="wicri:Area/Main/Curation">002006</idno><idno type="wicri:Area/Main/Exploration">000620</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease</title><author><name sortKey="Rojo, Ana I" sort="Rojo, Ana I" uniqKey="Rojo A" first="Ana I." last="Rojo">Ana I. Rojo</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</wicri:regionArea></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Espagne</country><wicri:regionArea>Dpto. de Bioquímica and Instituto de Investigaciones Biomédicas “Alberto Sols” UAM‐CSIC, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Innamorato, Nadia G" sort="Innamorato, Nadia G" uniqKey="Innamorato N" first="Nadia G." last="Innamorato">Nadia G. Innamorato</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</wicri:regionArea></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Espagne</country><wicri:regionArea>Dpto. de Bioquímica and Instituto de Investigaciones Biomédicas “Alberto Sols” UAM‐CSIC, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author><author><name sortKey="Martin Oreno, Ana M" sort="Martin Oreno, Ana M" uniqKey="Martin Oreno A" first="Ana M." last="Martín-Moreno">Ana M. Martín-Moreno</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</wicri:regionArea></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Dpto. de Neurobiología Celular, Molecular y Desarrollo, Instituto Cajal, CSIC, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="De Ceballos, Maria L" sort="De Ceballos, Maria L" uniqKey="De Ceballos M" first="María L." last="De Ceballos">María L. De Ceballos</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</wicri:regionArea></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Dpto. de Neurobiología Celular, Molecular y Desarrollo, Instituto Cajal, CSIC, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Yamamoto, Masayuki" sort="Yamamoto, Masayuki" uniqKey="Yamamoto M" first="Masayuki" last="Yamamoto">Masayuki Yamamoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai</wicri:regionArea><wicri:noRegion>Sendai</wicri:noRegion></affiliation></author><author><name sortKey="Cuadrado, Antonio" sort="Cuadrado, Antonio" uniqKey="Cuadrado A" first="Antonio" last="Cuadrado">Antonio Cuadrado</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED)</wicri:regionArea></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Espagne</country><wicri:regionArea>Dpto. de Bioquímica and Instituto de Investigaciones Biomédicas “Alberto Sols” UAM‐CSIC, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><orgName type="university">Université autonome de Madrid</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Glia</title><title level="j" type="abbrev">Glia</title><idno type="ISSN">0894-1491</idno><idno type="eISSN">1098-1136</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-04">2010-04</date><biblScope unit="volume">58</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="588">588</biblScope><biblScope unit="page" to="598">598</biblScope></imprint><idno type="ISSN">0894-1491</idno></series><idno type="istex">C2FD69B7B8C27492BD436920C88B658D0F43E23F</idno><idno type="DOI">10.1002/glia.20947</idno><idno type="ArticleID">GLIA20947</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0894-1491</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>heme oxygenase‐1</term><term>innate immune system</term><term>neurodegenerative diseases</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neural injury leads to inflammation and activation of microglia that in turn may participate in progression of neurodegeneration. The mechanisms involved in changing microglial activity from beneficial to chronic detrimental neuroinflammation are not known but reactive oxygen species (ROS) may be involved. We have addressed this question in Nrf2‐knockout mice, with hypersensitivity to oxidative stress, submitted to daily inoculation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) for 4 weeks. Basal ganglia of these mice exhibited a more severe dopaminergic dysfunction than wild type littermates in response to MPTP. The amount of CD11b‐positive/CD45‐highly‐stained cells, indicative of peripheral macrophage infiltration, did not increase significantly in response to MPTP. However, Nrf2‐deficient mice exhibited more astrogliosis and microgliosis as determined by an increase in messenger RNA and protein levels for GFAP and F4/80, respectively. Inflammation markers characteristic of classical microglial activation, COX‐2, iNOS, IL‐6, and TNF‐α were also increased and, at the same time, anti‐inflammatory markers attributable to alternative microglial activation, such as FIZZ‐1, YM‐1, Arginase‐1, and IL‐4 were decreased. These results were confirmed in microglial cultures stimulated with apoptotic conditioned medium from MPP+‐treated dopaminergic cells, further demonstrating a role of Nrf2 in tuning balance between classical and alternative microglial activation. This study demonstrates a crucial role of Nrf2 in modulation of microglial dynamics and identifies Nrf2 as molecular target to control microglial function in Parkinson's disease (PD) progression. © 2009 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Espagne</li><li>Japon</li></country><region><li>Communauté de Madrid</li></region><settlement><li>Madrid</li></settlement><orgName><li>Université autonome de Madrid</li></orgName></list><tree><country name="Espagne"><noRegion><name sortKey="Rojo, Ana I" sort="Rojo, Ana I" uniqKey="Rojo A" first="Ana I." last="Rojo">Ana I. Rojo</name></noRegion><name sortKey="Cuadrado, Antonio" sort="Cuadrado, Antonio" uniqKey="Cuadrado A" first="Antonio" last="Cuadrado">Antonio Cuadrado</name><name sortKey="Cuadrado, Antonio" sort="Cuadrado, Antonio" uniqKey="Cuadrado A" first="Antonio" last="Cuadrado">Antonio Cuadrado</name><name sortKey="De Ceballos, Maria L" sort="De Ceballos, Maria L" uniqKey="De Ceballos M" first="María L." last="De Ceballos">María L. De Ceballos</name><name sortKey="De Ceballos, Maria L" sort="De Ceballos, Maria L" uniqKey="De Ceballos M" first="María L." last="De Ceballos">María L. De Ceballos</name><name sortKey="Innamorato, Nadia G" sort="Innamorato, Nadia G" uniqKey="Innamorato N" first="Nadia G." last="Innamorato">Nadia G. Innamorato</name><name sortKey="Innamorato, Nadia G" sort="Innamorato, Nadia G" uniqKey="Innamorato N" first="Nadia G." last="Innamorato">Nadia G. Innamorato</name><name sortKey="Martin Oreno, Ana M" sort="Martin Oreno, Ana M" uniqKey="Martin Oreno A" first="Ana M." last="Martín-Moreno">Ana M. Martín-Moreno</name><name sortKey="Martin Oreno, Ana M" sort="Martin Oreno, Ana M" uniqKey="Martin Oreno A" first="Ana M." last="Martín-Moreno">Ana M. Martín-Moreno</name><name sortKey="Rojo, Ana I" sort="Rojo, Ana I" uniqKey="Rojo A" first="Ana I." last="Rojo">Ana I. Rojo</name></country><country name="Japon"><noRegion><name sortKey="Yamamoto, Masayuki" sort="Yamamoto, Masayuki" uniqKey="Yamamoto M" first="Masayuki" last="Yamamoto">Masayuki Yamamoto</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000620 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000620 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C2FD69B7B8C27492BD436920C88B658D0F43E23F
|texte= Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |